Literature DB >> 15006550

Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells.

Kenyon G Daniel1, Puja Gupta, R Hope Harbach, Wayne C Guida, Q Ping Dou.   

Abstract

Here we report that organic copper complexes can potently and selectively inhibit the chymotrypsin-like activity of the proteasome in vitro and in vivo. Several copper compounds, such as NCI-109268 and bis-8-hydroxyquinoline copper(II) [Cu(8-OHQ)(2)], can inhibit the chymotrypsin-like activity of purified 20S proteasome. In human leukemia cells, proteasome inhibition occurs within 15min after treatment, followed by apoptosis. Neither proteasome inhibition nor apoptosis occurs in non-transformed, immortalized human natural killer cells under the same treatment. Furthermore, proteasome inhibition and apoptosis induction were detected in prostate cancer cells treated with the ligand 8-OHQ alone following pre-treatment with copper(II) chloride. None of these events occurred in cells treated with copper(II) chloride alone, 8-OHQ alone (without growth in copper-enriched media), or nickel(II) chloride pre-treatment followed by 8-OHQ. Furthermore, we found that copper-mediated inhibition of purified 20S proteasome cannot be blocked by a reducing agent and that organic copper compounds do not generate hydrogen peroxide in the cells, suggesting that proteasome inhibition and apoptosis induction are not due to copper-mediated oxidative damage of proteins. Our results suggest that certain types of organic ligands could bind to tumor cellular copper, forming potent proteasome inhibitors and apoptosis inducers at copper concentrations found in tumor tissues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15006550     DOI: 10.1016/j.bcp.2003.10.031

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  58 in total

1.  Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistry.

Authors:  F Wang; P Jiao; M Qi; M Frezza; Q P Dou; B Yan
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 2.  Novel metals and metal complexes as platforms for cancer therapy.

Authors:  Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal:  Curr Pharm Des       Date:  2010-06       Impact factor: 3.116

3.  A novel gallium compound synergistically enhances bortezomib-induced apoptosis in mantle cell lymphoma cells.

Authors:  Christopher R Chitambar; David P Purpi
Journal:  Leuk Res       Date:  2010-03-24       Impact factor: 3.156

4.  Discovery of protein phosphatase 2C inhibitors by virtual screening.

Authors:  Jessica P Rogers; Albert E Beuscher; Marc Flajolet; Thomas McAvoy; Angus C Nairn; Arthur J Olson; Paul Greengard
Journal:  J Med Chem       Date:  2006-03-09       Impact factor: 7.446

Review 5.  New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer.

Authors:  Di Chen; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2008-06       Impact factor: 6.902

6.  Metal Ions Effectively Ablate the Action of Botulinum Neurotoxin A.

Authors:  Paul T Bremer; Sabine Pellett; James P Carolan; William H Tepp; Lisa M Eubanks; Karen N Allen; Eric A Johnson; Kim D Janda
Journal:  J Am Chem Soc       Date:  2017-05-19       Impact factor: 15.419

7.  Organic cadmium complexes as proteasome inhibitors and apoptosis inducers in human breast cancer cells.

Authors:  Zhen Zhang; Caifeng Bi; Daniela Buac; Yuhua Fan; Xia Zhang; Jian Zuo; Pengfei Zhang; Nan Zhang; Lili Dong; Q Ping Dou
Journal:  J Inorg Biochem       Date:  2013-02-21       Impact factor: 4.155

8.  Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells.

Authors:  Boris Cvek; Vesna Milacic; Jan Taraba; Q Ping Dou
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

9.  Discovery of novel proteasome inhibitors using a high-content cell-based screening system.

Authors:  Irena Lavelin; Avital Beer; Zvi Kam; Varda Rotter; Moshe Oren; Ami Navon; Benjamin Geiger
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

10.  NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner.

Authors:  Eswar Shankar; Chandreyi Basu; Brett Adkins; Wolfram Siede; Alakananda Basu
Journal:  J Mol Signal       Date:  2010-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.